The study is a prospective cohort study that included 400 subjects with MCI enrolled in at Huashan Hospital in Shanghai, China and a followed-up once annually for three years. The objectives are to identify individuals with MCI who convert to AD and to explore factors associated with the conversion. The observation time point is every 12 months and phone interview on 6th, 18th month. The primary endpoint was the time from diagnosis to the conversion from MCI to Probable AD Dementia. The secondary endpoints are the time to conversion from MCI to Possible AD Dementia or Probable AD Dementia, time to Conversion from MCI to All-cause Dementia, Overall survival, Changes in Neuropsychological examinations and Changes in MRI from baseline to the end of follow-up. The planned research duration was from Jan 2012 to Dec 2016.
A population-based prospective study of cerebro-cardiovascular diseases was begun in 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area of Kyushu Island in Japan. In addition, comprehensive surveys of cognitive impairment in the elderly of this town have been conducted since 1985. In 1988, a total of 1,228 residents aged ?60 years (91.1% of the total population in this age group) participated in a screening examination for the present study. After exclusion of 33 subjects who had dementia, 90 who had already had breakfast, 5 who were on insulin therapy, and 81 who could not complete the OGTT, a total of 1,019 subjects without dementia underwent the OGTT. From a total of 1,019 subjects, 2 who died before starting follow-up were excluded, and the remaining 1,017 subjects (437 men and 580 women) were enrolled in this study.
The subjects were followed up prospectively for 15 years, from December 1988 to November 2003 (mean 10.9 years; SD 4.1 years).
Tracking Parkinson’s, or the PRoBaND study, is a UK-based study of Parkinson’s disease funded entirely by Parkinson’s UK.
There is a wide variation of symptoms and features of Parkinson’s driven by both genetic and external factors. Our study aims to define and explain these variations by analysing the clinical expression of Parkinson’s in relation to genotypic variation. Tracking Parkinson’s is a multi-centre prospective longitudinal study, informed by epidemiological and biomarker data.
Participants were recruited into three categories:
- Recent onset patients (diagnosed within the last three years) are followed up at 6-month intervals for four years, then every 18-months for a further three years.
- Early onset (patients diagnosed before the age of 50) were followed up at one year.
- Relatives (siblings) of the participants are followed up after three years.
Since 2012, we have been running at 70 sites across the UK. Recruitment closed in November 2017 and our cohort consists of 2,270 people with Parkinson’s and 344 of their siblings.
This is a feasibility study which has a Longitudinal Cohort design, following up participants at selected time points over a 1 year duration. The study will recruit 2 distinct groups: (1) patients with symptoms of cognitive impairment, and (2) study partners who are cognitively normal. The patients recruited to group 1 will have been recently referred to a Memory Assessment Service by their GP with suspected Mild Cognitive Impairment (MCI) & mild dementia. All patients referred to a Memory Assessment Service for this reason will be potentially eligible for inclusion in the study. Close friends or family members involved in looking after the cognitively impaired participants will also be asked to participate as study partners to attempt to measure the impact that looking after a partner, friend or family member with memory problems can have on a carers Quality of Life and other variables such as financial burden. Both cognitively impaired participants and their study partners will be given the option of additionally participating in two sub-studies:
Mobile data collection: Using a web/mobile app to collect self-reported data on a more regular basis from home
Wearable device: Using a wearable device that looks like a watch to collect information on activity and sleep
The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.
The Parkinson’s Progression Marker Initiative (PPMI) is an observational, international study designed to establish biomarker defined cohorts and identify clinical, imaging, genetic and biospecimen Parkinson’s disease (PD) progression markers to accelerate disease modifying therapeutic trials. A total of 423 untreated PD, 196 Healthy Control (HC), 64 SWEDD (scans without evidence of dopaminergic deficit) subjects, and 65 Prodromal subjects (individuals with hyposmia or REM Sleep Behavior Disorder) were enrolled. PPMI is actively enrolling affected and unaffected individuals with genetic mutations in LRRK2, GBA, or SNCA through the end of 2018. For the most up to date enrollment numbers, please visit http://www.ppmi-info.org/study-design/study-cohorts/. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.
The Vallecas Project is developed in the Research Unit of the Alzheimer’s Center of the Reina Sofía Foundation by researchers of the CIEN Foundation. Its main objective is to determine a probabilistic algorithm for the identification of individuals at risk of dementia type Alzheimer’s disease (AD) in the course of a few years. This algorithm will be based on the combination of sociodemographic, clinical, neurological, neuropsychological, biological (from blood determinations) and neuroimaging (various 3 Tesla magnetic resonance modalities).
The recruitment phase of the Vallecas Project participants was extended from October 2011 to December 2013. Finally, a total of 1,213 volunteers aged between 70 and 85 and of both sexes were initially evaluated. Once included in the study, it is monitored annually for 5 years in order to assess the evolutionary profile of all participants, specifically identifying those who develop cognitive impairment and / or dementia. The cohort is being followed up annually for 4 years after the baseline.
The Mayo Clinic Study of Aging was designed to establish a prospective population-based cohort of subjects to study prevalence, incidence and risk factors for MCI and dementia. The study was conducted in Olmsted County, where several factors enhance the feasibility of population-based epidemiologic research. Most residents seek care within the community from essentially 2 providers, the Mayo Clinic and Olmsted Medical Center, along with their affiliated hospitals and medical facilities within the county. Both healthcare providers use a unit medical record which includes all outpatient and inpatient information for each patient. The study began October 1, 2004, and recruitment is ongoing to maintain a sample size of about 3,000 active participants. Participants are randomly selected from the Olmsted County population using a sex and age-stratified sampling scheme. Selected participants are invited to participate; exclusion criteria are persons who are in hospice or terminally ill or demented, but recruitment of persons with dementia began in 2015. Nearly 6,000 participants have been recruited to date. At the onset of the study, only 70-89 year olds were eligible. Recruitment of 50-69 year-olds began in 2012, and recruitment of 30-49 year olds began in 2014. Followup is performed every 15 months for 50 yrs and older; every 30 months if younger than 50 years by face-to-face visits in the Center, in-home, or by phone for a minority who decline either of the two but still would like to participate. Medical records are reviewed is used to identify prevalent and incident medical conditions (e.g. vascular diseases such as diabetes, hypertension) and incident dementia cases among persons lost to follow-up.
This project comprises of two complementary parts. One part is aimed at the development of innovative diagnostic techniques to detect molecular signatures of AD based on disturbances of amyloid metabolism and glutamate neurotransmission. In this part, the focus is on the two most promising diagnostic approaches in AD: (molecular) imaging techniques and molecular diagnostic tests of CSF. In the second part of this study, techniques for which proof-of-concept has been found in humans are applied in a large group of AD patients. These patients are recruited in an established network of 4 collaborating memory clinics in The Netherlands, which use a standardized diagnostic protocol and share an extensive common database. Furthermore, more mature molecular, structural, and functional imaging and molecular diagnostic CSF techniques as well as the conventional diagnostic work-up will be applied from the start of the study in patients from the same network of memory clinics.
Dementia with Lewy Bodies (DLB) is the second most common cause of neurodegenerative dementia in older people. The aim of LewyPro is to examine and characterise symptoms and brain changes during the prodromal period of LBD. Earlier diagnosis is important because it facilitates care planning, leads to earlier treatment of cognitive symptoms and enables earlier identification of other symptoms, including parkinsonism.
Lewy Pro is recruiting a group of people with mild cognitive impairment (MCI) and prodromal symptoms suggestive of Dementia with Lewy Bodies (DLB) and following them up annually to assess biomarker changes and clinical course. The initial assessment will include a detailed clinical assessment, a blood sample, a lumbar puncture for cerebrospinal fluid, and a DaTSCAN.
Last Update 21/09/2017